On May 6, 2020 Applied DNA Sciences Inc. (NASDAQ: APDN) ("Applied DNA" or the "Company") a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables diagnostics, pre-clinical nucleic acid-based therapeutic drug candidates, supply chain security, anti-counterfeiting and anti-theft technology, reported that it has received approximately $5.3 million in net proceeds calendar year to date as a result of the exercise of equity warrants (Press release, Applied DNA Sciences, MAY 6, 2020, View Source [SID1234557088]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Applied DNA issued approximately 2.6 million warrants in connection with an underwritten public offering that closed on November 15, 2019. Each warrant entitles its owner to purchase one share of common stock in the Company at a per share price of $5.25 until November 15, 2024. Approximately 1.5 million warrants associated with the November 15, 2019 offering remain outstanding.